Young-Woo Park, CEO of Y-Biologics - renowned for their library with diversity of 1011 - unveils their plan to be the first in Korea to develop the PD-1 antibody as a treatment for cancer. Mr Park provides his assessment of the current biotechnology environment in South Korea, and the growing interest of the sector for venture capital investments.
We started as a service provider but now we have transformed into a biotech company with great potential on the basis of excellence and expertise in antibody science
